These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Steinberg M; Silva M Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493 [TBL] [Abstract][Full Text] [Related]
5. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941 [TBL] [Abstract][Full Text] [Related]
6. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Juarez JG; Harun N; Thien M; Welschinger R; Baraz R; Pena AD; Pitson SM; Rettig M; DiPersio JF; Bradstock KF; Bendall LJ Blood; 2012 Jan; 119(3):707-16. PubMed ID: 22049516 [TBL] [Abstract][Full Text] [Related]
8. Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization. Liu W; Du W; Shang X; Wang L; Evelyn C; Florian MC; A Ryan M; Rayes A; Zhao X; Setchell K; Meller J; Guo F; Nassar N; Geiger H; Pang Q; Zheng Y Leukemia; 2019 Mar; 33(3):749-761. PubMed ID: 30254339 [TBL] [Abstract][Full Text] [Related]
9. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613 [TBL] [Abstract][Full Text] [Related]
10. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Pusic I; DiPersio JF Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162 [TBL] [Abstract][Full Text] [Related]
11. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Uy GL; Rettig MP; Cashen AF Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313 [TBL] [Abstract][Full Text] [Related]
12. Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization. Bisht K; McGirr C; Lee SY; Tseng HW; Fleming W; Alexander KA; Matsumoto T; Barbier V; Sims NA; Müller-Newen G; Winkler IG; Bonig H; Lévesque JP Leukemia; 2022 Feb; 36(2):333-347. PubMed ID: 34518644 [TBL] [Abstract][Full Text] [Related]
13. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815 [TBL] [Abstract][Full Text] [Related]
15. Platelet-derived circulating soluble P-selectin is sufficient to induce hematopoietic stem cell mobilization. Wang TF; Liou YS; Yang SH; Lin GL; Chiang YW; Lien TS; Li CC; Wang JH; Chang HH; Sun DS Stem Cell Res Ther; 2023 Oct; 14(1):300. PubMed ID: 37864264 [TBL] [Abstract][Full Text] [Related]
16. New agents in HSC mobilization. Domingues MJ; Nilsson SK; Cao B Int J Hematol; 2017 Feb; 105(2):141-152. PubMed ID: 27905003 [TBL] [Abstract][Full Text] [Related]
17. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Flomenberg N; Comenzo RL; Badel K; Calandra G Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838 [TBL] [Abstract][Full Text] [Related]